1 / 1

KYOTO

KYOTO. BP at follow-up: 133/76 mm Hg in both groups Composite CV events: 5.5% with valsartan vs. 10.2% with usual therapy Stroke/TIA: 1.5% vs. 3% Angina: 1.5% vs. 2.9% (p = 0.01) New-onset DM: 5.2% vs. 7.7% (p = 0.028).

cameo
Download Presentation

KYOTO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. KYOTO BP at follow-up: 133/76 mm Hg in both groups Composite CV events: 5.5% with valsartan vs. 10.2% with usual therapy Stroke/TIA: 1.5% vs. 3% Angina: 1.5% vs. 2.9% (p = 0.01) New-onset DM: 5.2% vs. 7.7% (p = 0.028) Trial design: Hypertensive Japanese patients with one or more CV risk factors were randomized to valsartan titrated to 160 mg daily (n = 1,517) vs. usual therapy without an ACE-I or an ARB (n = 1,514). Results (p < 0.001) (p = 0.015) % Conclusions • Among hypertensive Japanese patients with additional CV risk factors, the use of valsartan beneficial • Valsartan associated with a reduction in composite CV events, which was driven by fewer strokes/TIA and angina Composite CV events Stroke Valsartan Usual therapy Sawada T, et al. Eur Heart J 2009;Aug 31:[Epub]

More Related